Nová evropská doporučení pro léčbu hepatitidy C
| Title in English | New European guidelines concerning the treatment of hepatitis C |
|---|---|
| Authors | |
| Year of publication | 2015 |
| Type | Article in Periodical |
| Magazine / Source | Remedia |
| MU Faculty or unit | |
| Citation | |
| Field | Epidemiology, infectious diseases and clinical immunology |
| Keywords | hepatitis C-pegylated interferon; ribavirin; sofosbuvir; simeprevir; daclatasvir; ledipasvir; paritaprevir; ombitasvir; dasabuvir |
| Description | Treatment of chronic hepatitis C made extraordinary development in the last four years. The main change is related to the possibility of therapy with direct-acting antiviral; (DAA) either In combination with pegylated Interferon and ribavirin, or in Interferon-free or even ribavirin-free regimes. European Association for the Study of the Liver (EASL) Recommendations on treatment of hepatitis C from April 2015 pay attention predominantly to the fundamental changes in recommended therapeutic regimens of chronic hepatitis C infection. |